These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structural instability of plasmid biopharmaceuticals: challenges and implications. Oliveira PH; Prather KJ; Prazeres DM; Monteiro GA Trends Biotechnol; 2009 Sep; 27(9):503-11. PubMed ID: 19656584 [TBL] [Abstract][Full Text] [Related]
3. Engineering of bacterial strains and vectors for the production of plasmid DNA. Bower DM; Prather KL Appl Microbiol Biotechnol; 2009 Apr; 82(5):805-13. PubMed ID: 19205691 [TBL] [Abstract][Full Text] [Related]
4. Biomedical application of plasmid DNA in gene therapy: a new challenge for chromatography. Sousa F; Passarinha L; Queiroz JA Biotechnol Genet Eng Rev; 2010; 26():83-116. PubMed ID: 21415877 [TBL] [Abstract][Full Text] [Related]
5. Plasmid DNA for pharmaceutical applications. Schleef M; Schmidt T; Flaschel E Dev Biol (Basel); 2000; 104():25-31. PubMed ID: 11713820 [TBL] [Abstract][Full Text] [Related]
8. Plasmid DNA vaccines: assay for integration into host genomic DNA. Ledwith BJ; Manam S; Troilo PJ; Barnum AB; Pauley CJ; Griffiths TG; Harper LB; Schock HB; Zhang H; Faris JE; Way PA; Beare CM; Bagdon WJ; Nichols WW Dev Biol (Basel); 2000; 104():33-43. PubMed ID: 11713822 [TBL] [Abstract][Full Text] [Related]
9. The mechanism of naked DNA uptake and expression. Wolff JA; Budker V Adv Genet; 2005; 54():3-20. PubMed ID: 16096005 [TBL] [Abstract][Full Text] [Related]
10. Highly selective isolation of unknown mutations in diverse DNA fragments: toward new multiplex screening in cancer. Chakrabarti S; Price BD; Tetradis S; Fox EA; Zhang Y; Maulik G; Makrigiorgos GM Cancer Res; 2000 Jul; 60(14):3732-7. PubMed ID: 10919642 [TBL] [Abstract][Full Text] [Related]
11. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Chong SY; Egan MA; Kutzler MA; Megati S; Masood A; Roopchard V; Garcia-Hand D; Montefiori DC; Quiroz J; Rosati M; Schadeck EB; Boyer JD; Pavlakis GN; Weiner DB; Sidhu M; Eldridge JH; Israel ZR Vaccine; 2007 Jun; 25(26):4967-82. PubMed ID: 17335943 [TBL] [Abstract][Full Text] [Related]
12. Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA. Shamlou PA Biotechnol Appl Biochem; 2003 Jun; 37(Pt 3):207-18. PubMed ID: 12683955 [TBL] [Abstract][Full Text] [Related]
13. Analysis of DNA repeats in bacterial plasmids reveals the potential for recurrent instability events. Oliveira PH; Prather KJ; Prazeres DM; Monteiro GA Appl Microbiol Biotechnol; 2010 Aug; 87(6):2157-67. PubMed ID: 20496146 [TBL] [Abstract][Full Text] [Related]
14. Human clinical trials of plasmid DNA vaccines. Liu MA; Ulmer JB Adv Genet; 2005; 55():25-40. PubMed ID: 16291211 [TBL] [Abstract][Full Text] [Related]
15. Structural instability of small rolling circle replication plasmids from Selenomonas ruminantium. Pristas P; Ivan J; Javorsky P Plasmid; 2010 Sep; 64(2):74-8. PubMed ID: 20450933 [TBL] [Abstract][Full Text] [Related]
18. Upstream processing of plasmid DNA for vaccine and gene therapy applications. Tejeda-Mansir A; Montesinos RM Recent Pat Biotechnol; 2008; 2(3):156-72. PubMed ID: 19075863 [TBL] [Abstract][Full Text] [Related]
19. From plasmids to protection: a review of DNA vaccines against infectious diseases. Laddy DJ; Weiner DB Int Rev Immunol; 2006; 25(3-4):99-123. PubMed ID: 16818367 [TBL] [Abstract][Full Text] [Related]
20. Affinity chromatography approaches to overcome the challenges of purifying plasmid DNA. Sousa F; Prazeres DM; Queiroz JA Trends Biotechnol; 2008 Sep; 26(9):518-25. PubMed ID: 18675479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]